FindTrial
Sign In

Compassionate Use of Ubamatamab

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT07502716
Enrollment
Unknown
Registered
2026-03-31
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Medullary Carcinoma (RMC), Epithelioid Sarcoma

Brief summary

Provide Compassionate Use of Ubamatamab

Detailed description

Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.

Interventions

DRUGubamatamab

Sponsors

Regeneron Pharmaceuticals
Lead SponsorINDUSTRY

Eligibility

Inclusion criteria

Eligibility will be determined during the application review process.

Contacts

CONTACTRequests for compassionate use must be initiated by a treating physician Physicians should contact
Managedaccessrequests@regeneron.com844-734-6643

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 1, 2026